10-K: CapsoVision Faces Going Concern Amid Rising Losses, Delays

CapsoVision reported increased revenue but widening net losses and a going concern warning, signaling significant financial and operational challenges despite product development efforts.

Summary

• CapsoVision, a medical technology company specializing in GI-tract capsule endoscopy, reported revenue of $13.6 million for the year ended December 31, 2025, a 15% increase from $11.8 million in 2024.
• The company incurred a net loss of $25.3 million in 2025, a 27% increase from $19.9 million in 2024, with an accumulated deficit of $155.7 million as of December 31, 2025.
• Audited financial statements for 2025 and 2024 include a footnote raising substantial doubt about the company's ability to continue as a going concern, indicating a need for additional financing before year-end 2026.
• Research and development expenses increased by 21% to $18.3 million in 2025, primarily due to the development of new CMOS image sensors and ASICs.
• The first-generation CapsoCam Colon capsule's 510(k) submission was abandoned due to FDA inquiries, with resources redirected to a second-generation product targeting Q3 2026 FDA submission.
• CapsoCam Plus, the small bowel capsule, received FDA 510(k) clearance for pediatric use and telehealth supervision in December 2024, and an AI-assisted version is targeting FDA clearance by mid-2026.
• The company completed a private placement on March 16, 2026, raising $14.0 million through the issuance of 2,867,089 common shares at $4.883 per share.
• Two material weaknesses in internal control over financial reporting were identified as of December 31, 2024, and were not fully remediated by December 31, 2025, relating to IT general controls and segregation of duties.
• Management changes include the CFO stepping down in August 2025, with the Senior VP of Finance assuming principal financial officer duties, and the Senior Director of Clinical Affairs retiring in October 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a significantly negative filing. While revenue growth is present and R&D is active, the explicit 'going concern' warning, increasing net losses, and regulatory setbacks for key pipeline products indicate substantial financial and operational instability, outweighing positive developments.

Positives

• Revenue increased by 15% year-over-year to $13.6 million in 2025, driven by increased sales of CapsoCam Plus capsules.
• CapsoCam Plus received FDA 510(k) clearance in December 2024 for pediatric use and telemedicine supervision, expanding its addressable market.
• The company is actively developing a second-generation CapsoCam Colon capsule with improved imaging, AI, and a larger field of view, with a pivotal study underway and FDA submission targeted for Q3 2026.
• Ongoing investment in AI technology aims to improve pathology detection accuracy and streamline diagnostic processes, providing a competitive advantage.
• CapsoVision holds over 140 issued patents worldwide, protecting its core capsule camera and related technologies.
• The company successfully completed a private placement in March 2026, raising $14.0 million to support operations and clinical studies.

Negatives

• Net loss increased by 27% to $25.3 million in 2025, indicating widening losses despite revenue growth.
• The company's financial statements include a 'going concern' footnote, indicating substantial doubt about its ability to continue operations without additional capital.
• Gross margin slightly decreased from 54% in 2024 to 53% in 2025, partly due to increased customs and tariffs.
• The first-generation CapsoCam Colon 510(k) submission was abandoned due to FDA inquiries, leading to a delay in commercialization for this pipeline product.
• The FDA Breakthrough Device Designation application for pancreatic cancer detection was not approved due to a lack of defined diagnostic criteria, requiring further study and resubmission.
• Two material weaknesses in internal control over financial reporting were identified and not fully remediated, posing risks to financial reporting accuracy and timeliness.
• The company relies on single-source suppliers for critical components located in Asia (Taiwan and Japan), exposing it to geopolitical, trade, and natural disaster risks.
• Competition is intense, with established players like Medtronic having first-mover advantages and exclusive arrangements, and Asia-based competitors offering lower prices.

Risks

• History of net losses and expectation of additional losses in the foreseeable future.
• Substantial doubt about the ability to continue as a going concern, requiring additional financing to fund business and revenue growth plans.
• Reliance on CapsoCam Plus for near-term revenue, with growth subject to successful and timely execution of revenue growth strategy elements.
• CapsoCam Colon revenue not expected until mid-2027, contingent on FDA clearance for the second generation solution.
• Broad adoption of CapsoCam Colon depends on expanding beyond initial indicated patient populations, increasing accuracy, and achieving satisfactory completion rates.
• Longer-term efforts to expand GI-tract capsule endoscopy solutions beyond small bowel and colon pathologies may not succeed.
• Any failure or defect in the GI-tract capsule endoscopy solution could harm reputation, expose to liability, and reduce sales.
• Substantial geopolitical and trade risks (e.g., trade war, tariffs, supply chain interruptions) and natural disaster risks associated with business operations in Asia (Taiwan and Japan).
• Expansion risks when expanding in existing and entering into new foreign markets.
• Clinical results of various clinical studies (including CapsoCam Colon) may not be released in peer-reviewed publications.
• Delays in obtaining 510(k) clearance for the planned second generation of CapsoCam Colon solution.
• Regulatory challenges and delays in obtaining 510(k) clearance for CapsoCam capsules incorporating self-developed AI technology.
• Inadequate reimbursement from Medicare and other third-party payors could hinder commercialization.
• Failure to comply with regulatory requirements could lead to stringent penalties.
• Healthcare policy and funding/budgetary changes could materially adversely affect business.
• Changes to U.S. tariff measures and other potential changes in international trade relations could have a material adverse effect.
• Changes in tax laws or tax rulings could adversely affect effective tax rates, results of operations, and financial condition.
• Relationships with board-certified physicians are subject to various state laws, and current practices may not remain compliant.
• Products must be manufactured in accordance with applicable laws and regulations, with risk of recalls or production termination for non-compliance.
• Activities may subject the company to risks under federal and state laws prohibiting kickbacks and false or fraudulent claims.
• Failure to comply with the Foreign Corrupt Practices Act (FCPA), economic and trade sanctions regulations, and similar laws could subject the company to penalties.
• Risks associated with the use and development of artificial intelligence, including potential inaccuracies or biases in AI technology.
• Actual or perceived failures to comply with applicable data privacy and security laws, regulations, standards, and other requirements could adversely affect the business.
• Use of cloud-based CapsoCloud faces complicated compliance requirements, especially internationally and with government customers.
• Information technology system failures, cyberattacks, or deficiencies in cybersecurity could adversely affect business and operations.
• Inability to obtain, maintain, enforce, and protect intellectual property rights.
• Reliance on third-party open source software components and failure to comply with their licenses.
• Limitations on the ability to utilize net operating loss carryforwards and research and development tax credits.
• Material weaknesses in internal control over financial reporting could adversely affect reporting accuracy and timeliness.
• Litigation and other risks as a result of material weaknesses in internal control over financial reporting.
• Market price volatility of common stock.
• Provisions in charter documents and Delaware law could discourage a takeover.
• Product and professional liability suits could result in expensive litigation and substantial damages.
• Acquisitions could disrupt business, cause dilution, and reduce financial resources.
• Adverse effects from natural disasters and other catastrophic events.

Future Outlook

The company expects to continue incurring significant losses in the foreseeable future as it scales its business, invests in R&D, and expands sales and marketing. It anticipates needing to raise additional capital before year-end 2026 to fund operations and planned clinical studies. Commercialization of the AI-assisted CapsoCam Plus is expected shortly after FDA clearance by mid-2026, and the second-generation CapsoCam Colon is targeting FDA submission in Q3 2026, with revenues not expected until mid-2027. Longer-term plans include commencing feasibility studies for pancreatic cancer detection in Q2 2026 and clinical studies for esophageal varices screening in H1 2027, subject to funding and liquidity.

Management Comments

• Management believes that existing cash balances will not be sufficient to fund operations for at least the next 12 months after the date of issuance of these financial statements, even after the recent private placement.
• Management expects to continue to incur significant losses for the foreseeable future as we continue to build our operations and transition to operating as a public company, as well as advance our current and future products through clinical development.
• Management believes that our GI-tract capsule endoscopy solution is positioned to benefit from our existing sales and marketing structure, technological advancements, and increased telemedicine adoption.
• Management believes that our CapsoCam Colon, once FDA cleared and commercialized, will be a superior capsule endoscopy system that will expand the market for colon capsule endoscopy.
• Management expects to resubmit the Breakthrough Device Designation application for pancreatic cancer detection following the study, when additional data is available, potentially supplementing the regulatory pathway and approval for early pancreas cancer detection.

Industry Context

StockSavvy.ai notes that CapsoVision operates in a highly competitive and rapidly evolving medical device market, particularly in diagnostic imaging and endoscopic procedures. The company's focus on AI-assisted panoramic capsule endoscopy aligns with broader industry trends towards less invasive diagnostics and the integration of artificial intelligence for improved diagnostic yield and efficiency. However, the market is dominated by established players like Medtronic, which possess significant resources and first-mover advantages. The aggressive pricing strategies of Asia-based competitors also present a challenge. CapsoVision's pursuit of new indications like esophageal varices and pancreatic cancer reflects a strategic move into high-unmet-need areas, but these also entail substantial R&D and regulatory hurdles, typical for novel diagnostic technologies.

Comparison to Industry Standards

• CapsoVision's CapsoCam Plus is highlighted as the sole capsule endoscope with a 360 panoramic view available in the market, offering superior diagnostic yield compared to competitors' end-view systems (e.g., Medtronic's PillCam SB3, IntroMedic MiroCam) which provide limited tunnel or partial wall views. A 2019 study noted CapsoCam's 60% better visualization of the papilla and 97% exam completion rates compared to competitor systems.
• The CapsoCam solution is a zero-capex, wire-free data collection system with remote data analysis via CapsoCloud, contrasting with competitors' wired data recorders that incur upfront capital expenses and workflow complications for providers (e.g., Medtronic's PillCam systems).
• CapsoCam Colon (once FDA cleared) is expected to be the only colon capsule endoscopy system utilizing AI for automated polyp detection and proprietary 3D-sensing technology for accurate polyp size measurement, capabilities that competitive systems like Medtronic's PillCam COLON 2 lack.
• In the context of colon cancer screening, CapsoCam Colon aims to offer superior polyp detection accuracy and diagnostic yield compared to non-invasive tests like CTC, which showed a sensitivity of 26.8% for polyps >=6mm in a multicenter study, versus colon capsule endoscopy's 78.2%. Stool-based tests like Cologuard have high false-positive rates, with advanced neoplasia not detected by colonoscopy in 75% of Cologuard-positive cases in one study.
• For esophageal varices screening, CapsoVision believes its panoramic imaging will offer significant improvement in sensitivity and staging accuracy compared to Medtronic's PillCam, which in a prospective study correctly diagnosed and staged varices in only 64% of cases detected by endoscopy.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any litigation or legal proceedings that are likely to have a material adverse effect on the business.

Related Party Transactions

• On May 27, 2025, the company entered into a promissory note with Ching-Hang Shen, a beneficial owner of more than 5% of the company's common stock, for $1.0 million. The note was repaid on July 11, 2025, and 7,508 shares of common stock were issued to Mr. Shen.
• Incurred $1.207 million in 2025 and $0.320 million in 2024 for non-recurring engineering services with an R&D and manufacturing services vendor that holds an insignificant percentage of the company's capital stock.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from potential future equity financings due to the 'going concern' warning and need for additional capital. The market price of common stock may be volatile due to financial performance and regulatory setbacks. Lock-up agreements for pre-IPO shares expired in early 2026, potentially increasing selling pressure.
• **Employees:** Management changes occurred, including the CFO and Senior Director of Clinical Affairs. The company's ability to attract and retain key personnel is crucial for its success, especially in a competitive industry. Stock-based compensation is a component of employee incentives.
• **Customers (Gastroenterologists, Clinics, Hospitals):** Benefit from the CapsoCam Plus's panoramic view, telemedicine capabilities, and upcoming AI-assisted features. The delay in CapsoCam Colon's approval may impact the availability of advanced colon diagnostic tools. Customer retention rate is high at approximately 90%.
• **Suppliers:** The company relies on single-source suppliers in Asia for critical components, exposing them to geopolitical and trade risks that could disrupt supply and impact delivery of products.
• **Regulatory Bodies (FDA, SEC):** The company is subject to extensive regulation, including 510(k) clearance processes, post-market surveillance, and financial reporting requirements. Regulatory setbacks for CapsoCam Colon and the non-approval of the Breakthrough Device Designation highlight ongoing scrutiny. Material weaknesses in internal controls require remediation and ongoing oversight.

Next Steps

• Submit 510(k) application for the second-generation CapsoCam Colon capsule to the FDA in Q3 2026.
• Seek EU approval and commercialization for the second-generation CapsoCam Colon capsule shortly after FDA clearance.
• Obtain FDA clearance for the updated CapsoCam Plus with AI by mid-2026, followed by commercialization in the U.S. and EU.
• Target EU submission for CapsoCam Plus with AI in Q2 2026, with clearance anticipated in Q3 2026.
• Achieve full commercialization of a capsule delivery device in Q4 2026.
• Submit FDA 510(k) application for a patency capsule by the end of Q2 2026.
• Commence feasibility studies of CapsoCam's accuracy in detecting abnormalities indicative of pancreatic neoplasia in Q2 2026.
• Resubmit the FDA Breakthrough Device Designation application for pancreatic cancer detection after additional study data is available.
• Commence clinical studies of CapsoCam's accuracy in screening esophageal varices in cirrhotic patients in H1 2027.
• Continue to invest in improving AI algorithms for pathology detection and classification accuracy, and apply AI to streamline diagnostic and medical-report-generation processes.
• Implement remediation plans for identified material weaknesses in internal control over financial reporting, including replacing the ERP system and ensuring proper segregation of duties.
• Likely undertake additional capital-raising activities before year-end 2026 to fund operations and planned clinical studies.

Key Dates

Recommendation

The filing presents a highly concerning financial picture, with a clear 'going concern' warning for the next 12 months, indicating that the company's current cash and expected operating cash flows are insufficient to sustain operations. Despite revenue growth, net losses are significantly widening, and gross margins are declining. Key pipeline products, particularly CapsoCam Colon, face substantial regulatory delays and setbacks, pushing back potential revenue generation. The identified material weaknesses in internal controls further compound the risk profile. For a seasoned investor or institution, these fundamental financial and operational challenges, coupled with the explicit need for further capital raises in the near term, represent a high level of risk that would typically warrant divesting or avoiding the stock.

Keywords

Capsule Endoscopy, GI Tract Imaging, Medical Devices, AI Pathology Detection, CapsoCam Plus, CapsoCam Colon, FDA Clearance, Telemedicine, Colorectal Cancer Screening, Esophageal Varices, Pancreatic Cancer Detection, Going Concern, Supply Chain Risk, Intellectual Property, Healthcare Regulation, Financial Reporting, Diagnostic Imaging